Yepcef CV 200mg/125mg Tablet is a combination antibiotic formulation containing Cefixime 200mg and Clavulanic Acid 125mg, designed for the treatment of various bacterial infections. Cefixime, a third-generation cephalosporin, exhibits broad-spectrum bactericidal activity by inhibiting bacterial cell wall synthesis, effective against both Gram-positive and Gram-negative organisms. Clavulanic Acid, a beta-lactamase inhibitor, enhances the efficacy of Cefixime by preventing the enzymatic degradation of the antibiotic by beta-lactamase-producing bacteria, thereby extending its spectrum of activity. This synergistic combination is indicated for the management of respiratory tract infections, urinary tract infections, otitis media, skin and soft tissue infections, and other susceptible bacterial infections. The tablet formulation ensures convenient oral administration with good bioavailability. Yepcef CV should be prescribed based on susceptibility testing, and it is essential to complete the full course of therapy to prevent resistance development. Common adverse effects may include gastrointestinal disturbances such as diarrhea, nausea, and abdominal discomfort. Caution is advised in patients with a history of penicillin or cephalosporin allergy. Dose adjustment may be necessary in renal impairment. Overall, Yepcef CV 200mg/125mg Tablet is an effective antimicrobial agent for treating resistant bacterial infections where beta-lactamase production is a concern.